|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 中国间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌诊断专家共识(2013版)显示文摘随着分子医学进展和靶向药物的不断涌现,晚期非小细胞肺癌(NSCLC)的治疗已进入到个体化治疗的时代.目前临床应用的个体化靶向治疗主要针对表皮生长因子受体(EGFR)基因突变性和间变性淋巴瘤激酶(ALK)融合基因阳性肺癌,这两种基因变异型肺癌均具有明确的分子靶点、靶点检测技术及上市的靶向药物,临床疗效得到明显提高. | 张绪超 陆舜 张力 王长利 程颖 李甘地 Tony Mok Mok 黄诚 刘晓晴 王洁 王孟昭 张沂平 周建英 周晓燕 林冬梅 杨衿记 李慧 陈海泉 钟文昭 吴一龙 | 2013 | 中华病理学杂志2013，42，6： | 93 |
| 2 | 中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南显示文摘原发性肺癌(简称肺癌)是我国最常见的恶性肿瘤之一。根据国家癌症中心公布的2015年癌症统计数据显示,2015年,我国新发肺癌患者例数达73.3万,死亡例数60.0万。居所有恶性肿瘤之首,其中80%以上的患者为非小细胞肺癌(non—small cell lung cancer)。 | 张绪超 陆舜 黄诚 刘晓晴 杨衿记 宋勇 张力 廖美琳 王长利 程颖 李甘地 Tony Mok 莫树锦 王洁 王孟昭 张沂平 周建英 周晓军 周晓燕 林冬梅 胡成平 王凯 何勇 李慧 钟文昭 吴一龙 | 2018 | 中华病理学杂志2018，47，4： | 26 |
| 3 | Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma显示文摘AIM: To investigate the correlation between tissue ST6Gal I and serum msAFP in HCC patients, and to investigate their prognostic significance.METHODS: Preoperative sera,paired tumorous and non-tumorous tissues were collected from 19 consecutive patients who had undergone surgical resection of HCC.ST6Gal T activities in the tissues were measured by an in vitro microsomal enzyme activity assay. The percentages of tumor-specific msAFP in the sera were also estimated by an isoelectric focusing-immunoblotting assay.RESULTS: The tumor ST6Gal I activity was negatively correlated with serum msAFP percentage (r = -0.53,P = 0.019). Both decreased tumor ST6Gal I activity andincreased serum msAFP percentage were associatedwith poor tumor cell differentiation. Univariate analyses showed that both decreased tumor ST6Gal T activity (P = 0.028), increased serum msAFP percentage (P = 0.034) and poor tumor cell differentiation (P = 0.031)were associated with shorter overall survival. Multivariate analysis using the Cox regression model showed that the preoperative serum msAFP percentage (P = 0.022)and tumor cell differentiation status (P = 0.048) were independent prognostic indicators for patient overall survival.CONCLUSION: Our results indicate that the presence of msAFP in blood circulation is associated with a decreased activity of ST6Gal I activity in HCC. Both tissue ST6Gal I and serum msAFP are potential prognostic markers for patients with operable HCC. | Terence CW Poon Clarissa HS Chiu Paul BS Lai Tony SK Mok Benny Zee Anthony TC Chan Joseph JY Sung Philip J Johnson | 2005 | World Journal of Gastroenterology2005，11，42： | 4 |
| 4 | Management of Hepatocellular Carcinoma: Beyond Sorafenib显示文摘 | Stephen Chan Tony Mok Brigette Ma | 2012 | Current Oncology Reports2012，，3： | 2 |
| 5 | A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma显示文摘 | Stephen L. Chan Frankie K. F. Mo Cesar S. C. Wong Charles M. L. Chan Linda K. S. Leung Edwin P. Hui Brigette B. Ma Anthony T. C. Chan Tony S. K. Mok Winnie Yeo | 2011 | Cancer2011，，16： | 2 |
| 6 | An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma显示文摘 | George P. Kim Michelle R. Mahoney Daniel Szydlo Tony S. K. Mok Robert Marshke Kyle Holen Joel Picus Michael Boyer Henry C. Pitot Joseph Rubin Philip A. Philip Anna Nowak John J. Wright Charles Erlichman | 2012 | Investigational New Drugs2012，，1： | 2 |
| 7 | Phase III, randomized, open‐label, first‐line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non‐small‐cell lung cancer: evaluation of patients recruited from mainland China显示文摘 | Yi‐Long WU Da‐Tong CHU Baohui HAN Xuyi LIU Li ZHANG Caicum ZHOU Meilin LIAO Tony MOK Haiyi JIANG Emma DUFFIELD Masahiro FUKUOKA | 2012 | Asia‐Pacific Journal of Clinical Oncology2012，，3： | 1 |
| 8 | Phase III,randomised,open-label,first-linestudyofgefitinibvs carboplatin/paclitaxelin clinically selected patients with advanced non-small cell lung cancer(IPASS)显示文摘 | Tony Mok Yi-Long Wu Sumitra Thongprasert | 2008 | Ann Oncol2008，19，8： | 1 |
| 9 | Phase Ⅲ, randomised,open - label,first-line study of gefitinib vs carbo- platin/paclitaxel in clinically selected patients with advanced non - small cell lung cancer ( IPASS ) 显示文摘 | Tony Mok Yi - Long Wu Sumitra Thongprasert | 2008 | Ann Oncol2008，19，8： | 1 |
| 10 | Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung Cancer显示文摘Objective: To analyze the outcomes of patients who received TKI immediately after the first-line without progression as maintenance treatment (immediate group) vs. those received delayed treatment upon disease progression as second-line therapy (delayed group). Methods: The study included 159 no-small-cell lung cancer (NSCLC) patients who received gefitinib or erlotinib as maintenance treatment in the immediate group (85 patients) or as second-line therapy in the delayed group (74 patients). The primary end point was progression-free survival (PFS). EGFR mutation status was detected using denaturing high-performance liquid chromatography (DHPLC). Results: PFS was 17.3 and 16.4 months in the immediate and delayed groups, respectively (hazard ratio [HR], 0.99; 95% Confidence Interval [CI]: 0.69-1.42; P=0.947). In a subgroup analysis that included only patients with EGFR mutation, however, PFS was significantly longer in the immediate group than in the delayed group (HR, 0.48; 95% CI: 0.27-0.85; P=0.012). In patients with wild type EGFR, the risk for disease progression was comparable between the two groups (HR, 1.23; 95% CI: 0.61-2.51; P=0.564). No significant difference was demonstrated between the immediate and delayed group in terms of the overall survival (OS) (26.1 months vs. 21.6 months, respectively; HR=0.53; 95% CI: 0.27 to 1.06; P=0.072). There was also no difference in the incidence of adverse events between the two groups. Conclusions: EGFR TKI maintenance improves PFS in patients with EGFR mutation. Prospectively designed clinical studies that compare TKI immediate vs. delayed treatment after first-line chemotherapy upon disease progression are needed. | Zhi-jie Wang Tong-tong An Tony Mok Lu Yang Hua Bai Jun Zhao Jian-chun Duan Mei-na Wu Yu-yan Wang Ping-ping Li Hong Sun Ping Yang Jie Wang | 2011 | Chinese Journal of Cancer Research2011，23，2： | 1 |
| 11 | Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma显示文摘 | Tony S Mok Yi-Long Wu Sumitra Thongprasert et aI | 2009 | N Engl J Med2009，361，10： | 1 |
| 12 | Management of Hepatocellular Carcinoma: Beyond Sorafenib显示文摘 | Stephen L. Chan Tony Mok Brigette B. Y. Ma | 2012 | Current Oncology Reports2012，，3： | 1 |
| 13 | Phase Ⅲ,randomized,open-label,first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (IPASS)显示文摘 | Tony Mok | 2008 | Annals of Ontology2008，19，8： | 1 |
| 14 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations显示文摘 | Lecia V. Sequist James Chih-Hsin Yang Nobuyuki Yamamoto Kenneth O’Byrne Vera Hirsh Tony Mok Sarayut Lucien Geater Sergey Orlov Chun-Ming Tsai Michael Boyer Wu-Chou Su Jaafar Bennouna Terufumi Kato Vera Gorbunova Ki Hyeong Lee Riyaz Shah Dan Massey Victori | 2013 | Journal of Clinical Oncology2013，，27： | 1 |
| 15 | Population-based differences in treatment outcome following anticancer drug therapies显示文摘 | Brigette BY Ma Edwin P Hui Tony SK Mok | 2010 | Lancet Oncology2010，，1： | 1 |
| 16 | Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations显示文摘 | James Chih-Hsin Yang Vera Hirsh Martin Schuler Nobuyuki Yamamoto Kenneth J. O’Byrne Tony S.K. Mok Victoria Zazulina Mehdi Shahidi Juliane Lungershausen Dan Massey Michael Palmer Lecia V. Sequist | 2013 | Journal of Clinical Oncology2013，，27： | 1 |
| 17 | Liver resection after irinotccan 5-fluorourac and folinic acid for patients with unresectahle colorectal liver metastases: a muhicenter phase II study by the Cancer Therapeutic Research Group显示文摘 | WingM Ho Ma B Tony Mok | 2005 | Med Oncol2005，22，3： | 1 |
| 18 | Bowel obstruction with intestinal lipomatosis显示文摘 | Yen-Dun Tony Tzeng Shiuh-Inn Liu Ming-Chieh Yang King-Tong Mok | 2011 | Digestive and Liver Disease2011，，2： | 1 |
| 19 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations显示文摘 | Lecia V. Sequist James Chih-Hsin Yang Nobuyuki Yamamoto Kenneth O’Byrne Vera Hirsh Tony Mok Sarayut Lucien Geater Sergey Orlov Chun-Ming Tsai Michael Boyer Wu-Chou Su Jaafar Bennouna Terufumi Kato Vera Gorbunova Ki Hyeong Lee Riyaz Shah Dan Massey Victori | 2013 | Journal of Clinical Oncology2013，，27： | 1 |
| 20 | Maintenance therapy in non small cell lung cancer: a new treatment paradigm显示文摘 | Tony S K Mok T S Ramalingam S S | 2009 | Cancer2009，115，22： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员